KOL kliniske forsøg i Maryland
16 studier for KOL søger deltagere på steder i Maryland.
Byer i Maryland
Officiel studietekst (engelsk)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Oxon Hill
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 2. okt. 2026 · NCT06283966Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Johns Hopkins Bayview Medical Center- Site Number : 8400076, Baltimore
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 1. okt. 2026 · NCT07190222A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- Johns Hopkins Bayview Medical Center- Site Number : 8400009, Baltimore
RekruttererFase 4
Alder 40 til 85 · Alle køn · Opdateret 22. sep. 2026 · NCT07053423A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Baltimore
- Research Site, Baltimore
RekruttererFase 2
Alder 40 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT07082738Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- Johns Hopkins University, Baltimore
RekruttererFase 2
Alder 40 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT07059091A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Baltimore
- Research Site, Potomac
- Research Site, Rosedale
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 3. sep. 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Baltimore
- Research Site, Columbia
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 3. sep. 2026 · NCT06883305STRIVE Post-Market Registry Study
- University of Maryland, Baltimore
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 3. aug. 2026 · NCT04302272Multi-Center Clean Air Randomized Controlled Trial in COPD
- University of Maryland, Baltimore
- Johns Hopkins, Baltimore
- Tidal Health, Salisbury
RekruttererFase 3
Alder 40 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT06376994SPIROMICS Study of Early COPD Progression (SOURCE)
- Johns Hopkins Bayview Medical Center, Baltimore
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 30 til 55 · Alle køn · Opdateret 3. jun. 2026 · NCT05033990Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Rockville
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 9. apr. 2026 · NCT06961214OMEGA - Dietary Intervention - COPD Trial
- Johns Hopkins Bayview Campus, Baltimore
Rekrutterer
Alder 40 og opefter · Alle køn · Opdateret 16. mar. 2026 · NCT05297279Trial to Determine Effective Aspirin Dose in COPD
- Johns Hopkins Bayview Medical Center, Baltimore
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 16. mar. 2026 · NCT05265299Effectiveness of the WearME System for COPD Severity and Respiratory Function
- Johns Hopkins, Baltimore
- TidalHealth, Salisbury
RekruttererObservationsstudie
Alder 21 til 100 · Alle køn · Opdateret 9. sep. 2025 · NCT06751537Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Ascension St. Agnes Hospital, Baltimore
RekruttererObservationsstudie
Alder 50 og opefter · Alle køn · Opdateret 5. aug. 2025 · NCT06122077myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- University of Maryland - Baltimore, Baltimore
Rekrutterer
Alder 30 og opefter · Alle køn · Opdateret 6. feb. 2025 · NCT05204888Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.